Revenue: As of FY2026 Q3, the actual value is USD 383.5 M, beating the estimate of USD 367.02 M.EPS: As of FY2026 Q3, the actual value is USD 0.59, beating the estimate of USD 0.57.EBIT: As of FY2026 Q3, the actual value is USD 42.7 M.<h4>Financial Highlights for the Three Months Ended March 31, 2026</h4><ul><li>Net sales were $383.5 million, an increase of $35.7 million or 10%.</li><li>Net income was $24.0 million, an increase of $3.1 million or 15%.</li><li>Adjusted EBITDA was $60.8 million, an increase of $5.9 million or 11%.</li><li>Adjusted net income was $31.2 million, an increase of $5.0 million or 19%.</li><li>Gross profit was $125.7 million, an increase of $21.1 million or 20%.</li><li>Gross margin increased by 270 basis points to 32.8% of net sales, compared to 30.1% in the prior year period.</li><li>Selling, general and administrative expenses (SG&amp;A) were $81.0 million, an increase of $10.0 million or 14%.</li><li>Operating income was $44.7 million, an increase of $11.1 million or 33%.</li><li>Interest expense, net, was $10.4 million, an increase of $1.1 million.</li><li>Foreign currency losses, net, were $1.9 million, compared to $5.5 million of net gains in the prior year period.</li><li>Provision for income taxes was $8.3 million, a decrease of -$0.5 million or -6%.</li><li>The effective income tax rate was 25.7%, compared to 29.7% in the prior year period.</li><li>The adjusted effective income tax rate was 24.6%, compared to 25.8% in the prior year period.</li></ul><h4>Segment Net Sales for the Three Months Ended March 31, 2026</h4><ul><li>Animal Health: Net sales were $291.2 million, an increase of $32.8 million or 13%.<ul><li>MFAs and other net sales increased by $24.1 million or 13% to $205.8 million.</li><li>Nutritional specialty products net sales increased by $3.5 million or 8% to $46.8 million.</li><li>Vaccines net sales increased by $5.2 million or 16% to $38.6 million.</li></ul></li><li>Mineral Nutrition: Net sales were $73.4 million, an increase of $6.6 million or 10%.</li><li>Performance Products: Net sales were $18.9 million, a decrease of -$3.8 million or -17%.</li></ul><h4>Segment Adjusted EBITDA for the Three Months Ended March 31, 2026</h4><ul><li>Animal Health: Adjusted EBITDA increased by $8.0 million to $71.1 million.</li><li>Mineral Nutrition: Adjusted EBITDA decreased by -$0.6 million to $5.1 million.</li><li>Performance Products: Adjusted EBITDA decreased by -$1.1 million to $2.2 million.</li><li>Corporate: Corporate expenses increased by -$0.3 million to -$17.7 million.</li></ul><h4>Balance Sheet and Cash Flows (as of or for the twelve months ended March 31, 2026)</h4><ul><li>Free cash flow was $12.8 million for the twelve months ended March 31, 2026.</li><li>The gross leverage ratio was 3.1x as of March 31, 2026.</li><li>Total debt was $740.9 million.</li><li>Adjusted EBITDA for the twelve months ended March 31, 2026, was $240.7 million.</li><li>Cash and short-term investments were $77.5 million as of March 31, 2026.</li><li>Phibro Animal Health Corporation’s revolving credit facility was increased by $125 million to an aggregate commitment of $435 million on April 28, 2026.</li></ul><h4>Fiscal Year 2026 Financial Guidance</h4>Phibro Animal Health Corporation updated its fiscal year 2026 guidance, projecting net sales of $1.46 billion to $1.50 billion, net income of $92 million to $100 million, and adjusted EBITDA of $247 million to $255 million. The company also expects diluted EPS of $2.25 to $2.44, adjusted net income of $122 million to $127 million, and an adjusted diluted EPS of $2.98 to $3.10. The adjusted effective tax rate is anticipated to be approximately 25%.

Phibro Animal Health | 8-K: FY2026 Q3 Revenue Beats Estimate at USD 383.5 M